Skip to content
Menu

Veradermics, Incorporated MANE

Full chart Compare
Set alert

Price alert · MANE

All alert types
124.39 USD -0.47 (-0.38%)

Regular-session close

123.00 -1.39 -1.12%

Pre-market · Nov 20, 7:49 AM ET

121.91 Day range 128.69
32.00 52-week range 156.63
YTD
+229.51%
1 year
+229.51%

5D -9.75 (-7.31%)

125130FriMonTueWedThu123.63
Market cap
5.25B
EPS (ttm)
-3.89
Shares out
42.20M
Forward P/E
-48.19
YTD return
+229.51%
1-year return
+229.51%
50-day average
123.76
200-day average
96.54
Enterprise value
4.47B
Volume
293.03K
Avg volume
738.51K
Open
125.98
Previous close
124.86
Day's range
121.91 – 128.69
52-week range
32.00 – 156.63
Analysts
Strong Buy
Price target
187.33 (+50.6%)
Earnings date
Mar 29, 2027

Key statistics

Price / book
6.59
Free cash flow
-55.22M
Total cash
798.35M
Total debt
371.00K
Return on equity
-23.12%
Short % of float
12.27%

Fundamental scorecard

4 of 25 checks passed on MANE’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
MANE Revenue — quarterly 0
MANE Net income — quarterly -21.00M
MANE EPS — quarterly -0.50

Earnings

MANE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 29, 2027Mar 30, 2027-0.64———
Nov 10, 2026Sep 30, 2026-0.56227-0.50+0.06+11.07%
Aug 11, 2026Jun 30, 2026-0.64756-0.58+0.07+10.43%
May 12, 2026Mar 31, 2026-0.56-1.32-0.76-135.71%
Feb 25, 2026Dec 31, 2025-1.81-1.63+0.19+10.31%
Dec 3, 2025Sep 30, 2025—-1.63——

Upgrades / downgrades

MANE analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026CitigroupmainBuyBuy
Nov 9, 2026Leerink PartnersmainOutperformOutperform
Oct 22, 2026B. Riley SecuritiesmainBuyBuy
Oct 19, 2026Cantor FitzgeraldreitOverweightOverweight
Oct 19, 2026NeedhammainBuyBuy
Jul 16, 2026CitigroupmainBuyBuy

About Veradermics, Incorporated

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on MANE — it syncs with the Stock Master app.

Insider holders

MANE insider holders
InsiderRelationLatest transactionDateShares held
CHILDS JOHN WDirectorSaleAug 11, 20260
CORIC VLADIMIRDirectorPurchaseFeb 4, 20260
DURSO TIMOTHY AUGUSTChief Technology OfficerConversion of Exercise of derivative securityAug 16, 202678,142
ENRIGHT PATRICK G.DirectorSaleNov 10, 20260
GRANT-KELS JANE M. M.D.DirectorConversion of Exercise of derivative securityFeb 4, 20262,455
LONGITUDE CAPITAL PARTNERS V, LLCBeneficial Owner of more than 10% of a Class of SecurityPurchaseFeb 4, 20260

Institution ownership

MANE institution ownership
Holder% heldSharesValueReported
Montanova Capital LLC8.81%3,718,970462.57MSep 29, 2026
FMR, LLC7.26%3,062,338380.89MSep 29, 2026
JPMORGAN CHASE & CO5.62%2,372,707295.12MSep 29, 2026
SR One Capital Management, LP4.93%2,080,119258.73MSep 29, 2026
Citadel Advisors Llc4.85%2,048,475254.79MSep 29, 2026
Blackrock Inc.4.57%1,929,832240.03MSep 29, 2026

Fund ownership

MANE fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund1.95%824,223102.52MSep 29, 2026
abrdn Healthcare Investors1.49%627,84178.09MJun 29, 2026
abrdn Healthcare Opportunities Fund1.49%626,97777.98MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.47%618,41676.92MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.35%570,37670.94MSep 29, 2026
abrdn World Healthcare Fund0.81%341,88342.52MJun 29, 2026